+19.5%
SNPS vs MRNA
-70.5%
+90.0%
-42.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | +0.7% | +0.3% | +1.0% |
| 7D | -4.6% | -8.2% | +3.6% | -4.1% |
| 30D | -3.3% | +125.6% | -128.9% | -12.9% |
| 3M | -13.8% | +197.1% | -210.8% | -26.3% |
| 6M | -8.2% | +148.5% | -156.7% | -19.6% |
| YTD | -15.4% | +363.3% | -378.7% | -33.7% |
| 1Y | +2.4% | +462.0% | -459.6% | -22.9% |
| 3Y | -13.5% | +26.9% | -40.4% | -22.2% |
| 5Y | +19.5% | -69.6% | +89.1% | +17.5% |
| All | +19.5% | -70.5% | +90.0% | +17.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling